Archive

Ivermectin mass treatment in perspective

Written by | 17 Feb 2021

Ivermectin is a good treatment to use interim to and complementary to immunisations, according to Dr David Scheim, one of the authors of a study of mass treatment for covid-19 […]

Ivermectin dosing and distribution for mass treatment

Written by | 16 Feb 2021

Dr David Scheim, one of the authors of a recent study in Peru, describes the doses of ivermectin that were used and the strategies for effective mass distribution. https://www.youtube.com/watch?v=MSkKU18VlNo […]

The impact of covid-19 on lung cancer care

Written by | 4 Feb 2021

Delayed diagnoses and more patients with advanced cancers were consequences of the coronavirus pandemic, according to Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado. The coronavirus […]

The changing treatment landscape in lung cancer

Written by | 3 Feb 2021

Modern lung cancer treatment has changed the outlook for lung cancer patients considerably and interesting trial results are expected this year, according to Dr Erin Schenk, Assistant Professor, […]

Improved disease-free survival with osimertinib in EGFR+ lung cancer

Written by | 2 Feb 2021

Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado describes the results of the ADAURA trial and the implications for her practice. The other trial that has […]

Immunotherapy vs chemotherapy for lung cancer: 5-year survival

Written by | 1 Feb 2021

IMI interviewed Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado to find out about key trial results in lung cancer and the implications for patient care. […]

Ivermectin meta-analysis – the implications

Written by | 27 Jan 2021

Dr Tess Lawrie, Director of the Evidence-based Medicine Consultancy Ltd, describes the implications of her recently-published meta-analysis of ivermectin trials for covid-19. https://www.youtube.com/watch?v=fh5iGkX8Vp4 Dr Lawrie is now trying to make […]

Ivermectin meta-analysis – the findings

Written by | 26 Jan 2021

Dr Tess Lawrie, Director of the Evidence-based Medicine Consultancy Ltd, describes the key findings from her recently-published meta-analysis of ivermectin trials for covid-19. https://www.youtube.com/watch?v=WTTqKSYHOM8 The first finding was that […]

Ivermectin meta-analysis – the background

Written by | 25 Jan 2021

IMI interviewed Dr Tess Lawrie, Director of the Evidence-based Medicine Consultancy Ltd, to find out more about her recently-published meta-analysis of ivermectin trials for covid-19. https://www.youtube.com/watch?v=Qnjz0WlDxPc The Evidence-based Medicine […]

Comorbidities and RA – study methodology

Written by | 9 Jan 2021

A recent Canadian study examining comorbidities before and after the diagnosis of rheumatoid arthritis (RA) used distance matrices to match RA cases to controls with similar medical histories. The […]

Comorbidities and RA – study findings

Written by | 7 Jan 2021

A recent Canadian study examining comorbidities before and after the diagnosis of rheumatoid arthritis (RA) produced a number of interesting findings, Dr Mark Tatangelo, the lead researcher explains. This study […]

Investigating comorbidities and rheumatoid arthritis

Written by | 6 Jan 2021

Rheumatoid arthritis (RA) affects about one percent of the population in the UK and comorbidities are reported to be common. A recent study from Canada was designed to […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.